Bullish & Foolish
Full GTBP fundamentals All 466 on the Survival Watch

GTBPGT BIOPHARMA, INC.

Is GT Biopharma struggling financially?

Yes, by its own account. GT Biopharma told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

11/100

Critical

Sector
Biotech/Pharma
Market cap
$13.0M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.0M

÷

Cash burned over the last 12 months

$22.1M

What GT Biopharma told the SEC

March 31, 2026, the Company recorded a net loss of approximately $ 2.8 million and used cash in operations of approximately $ 2.5 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December…

GT BIOPHARMA, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 1250.8% share-count increase The company issued stock. Each share now owns 92.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt